Medicines Law & Policy’s director, Ellen ’t Hoen, receives high Netherlands honour for her...
Ellen 't Hoen has been appointed Officer of the Order of Oranje-Nassau, a royal award which recognises those who merit particular appreciation from society...
Never say never – Why the High Income Countries that opted-out from the Art....
To limit the ability of patent owners to charge excessive prices for patented medicines, countries can grant compulsory licences which permit others to produce...
Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
Covid-19 and the comeback of compulsory licensing
The Covid-19 outbreak raises many questions, including some we can answer using experiences gained in previous disease outbreaks. Here is one: how to deal...
Cystic Fibrosis Buyers Club Shows the UK Government The Way
The move by a group of parents of children with cystic fibrosis (CF) to set up a buyers club to gain access to treatments...
Drug Price Transparency Calls Move from South Africa to World Health Assembly
by Katrina Perehudoff and Jennifer Sellin
Over 30 states and 40 business and civil society groups debated strategies for affordable and sustainable medicines prices at...
Humiragate: AbbVie’s desperate attempts to keep its monopoly
A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...
Time to put a stop to the abuse of orphan drug regulation- the latest...
Today, the Dutch Medical Journal (Nederlands Tijdschrift voor Geneeskunde) reported on the case of lutetium-octreotaat, a cancer drug developed by researchers in the Dutch...
“The diseases were in the South and the drugs were in the North”: Ellen...
Ellen 't Hoen discusses the HIV epidemic in the 90's, which hit sub-Saharan Africa particularly hard, and was exacerbated by the lack of availability...
Gilead’s sofosbuvir patent in India – options for global access to new hepatitis C...
Earlier this month the US pharmaceutical company Gilead obtained a patent in India for sofosbuvir, part of a treatment of hepatitis C that became...